Transcatheter Aortic Valve Replacement (TAVR)
Transcatheter Aortic Valve Replacement (TAVR) has fundamentally altered the treatment of aortic stenosis, moving from a niche procedure for "inoperable" patients to a standard of care for many low-risk individuals. Unlike traditional open-heart surgery, which requires a sternotomy and the use of a heart-lung machine, TAVR involves placing a replacement valve via a catheter, typically through the femoral artery. This minimally invasive approach significantly reduces recovery time, hospital stays, and procedural trauma, making it a preferred option for an aging population.
In 2026, the discussion has shifted toward "valve durability" and the management of younger patients. As the procedure is increasingly performed on individuals in their early 70s or younger, clinicians are closely monitoring how these prosthetic valves perform over a decade or more. Recent data from long-term trials, such as the PARTNER 3 study, suggest that TAVR valves maintain hemodynamics comparable to surgical valves for at least seven years, providing a "stamp of approval" for their use in broader populations. However, the potential need for "TAVR-in-TAVR"—placing a second transcatheter valve inside a failing first one—is a topic of intense technical research.